ArticleFrontiers in oncology2025
Retrospective study from a single center to comparison of diagnostic value of three thyroid imaging reporting and data systems in Bethesda III/IV thyroid nodules.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Do thyroid nodules in the isthmus carry a higher risk of malignancy? A systematic review and meta-analysis.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: To compare the diagnostic value of ACR Thyroid Imaging Reporting and Data System (TI-RADS), K-TIRADS, and C-TIRADS in Bethesda III/IV thyroid nodules. Methods: This single-center retrospective study classified 80 Bethesda stage III/IV thyroid nodules from 80 patients between January 2020 and July 2023 according to three different systems. Diagnostic performance was evaluated using receiver operating characteristic curves, with histopathological diagnosis serving as the reference standard. Results: Overall, 41/80 (51.2%) nodules were malignant and 39/80 (48.8%) were benign. The malignancy rates for Bethesda type III and IV nodules were 50.7% and 55.6%, respectively. The malignancy risk in thyroid nodules increased with higher TI-RADS categories ( Conclusion: All three TI-RADS systems have diagnostic value in differentiating benign from malignant Bethesda III/IV nodules, With C-TIRADS showing the highest area under the curve(AUC), suggesting its potential utility in clinical evaluation and management of such nodules, particularly in Chinese populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.